Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer.

Autor: Claessens AKM; Department of Medical Oncology, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands., Busschbach JJV; Department of Psychiatry, Section of Medical Psychology and Psychotherapy, Erasmus Medical Centre, Rotterdam, The Netherlands., Ramaekers BLT; Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre, Maastricht, The Netherlands., Erdkamp FLG; Department of Medical Oncology, Zuyderland Medical Centre, Geleen, The Netherlands., Bouma JM; Department of Trial Registration, Comprehensive Cancer Centre the Netherlands, Rotterdam, The Netherlands., van Leeuwen-Stok AE; Dutch Breast Cancer Research Group, BOOG Study Center, Amsterdam, The Netherlands., Tjan-Heijnen VCG; Department of Medical Oncology, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands., Bos MEMM; Department of Medical Oncology, Erasmus Medical Centre, Rotterdam, The Netherlands.
Jazyk: angličtina
Zdroj: Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2022 May; Vol. 61 (5), pp. 619-624. Date of Electronic Publication: 2022 Feb 09.
DOI: 10.1080/0284186X.2022.2033832
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje